Improvements in Clinical Cancer Care Associated with Integration of Personalized Medicine
Open Access
- 20 September 2024
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (9) , 997
Abstract
Background: While adoption of personalized medicine (PM) continues to increase in clinical oncology, there is limited data connecting the level of PM adoption at a given institution to improved clinical outcomes for patients. The purpose of this study was to analyze the correlation between health care providers’ scores on a previously described PM integration framework and two outcome measures: the use of targeted therapy and clinical trial enrollment. Methods: This study was conducted using real-world data (RWD) from the Syapse® Learning Health Network (LHN). The PM integration score for six community hospital systems in the LHN was calculated and subsequently correlated with the two outcome measures. Results: Across six institutions, a strong correlation between PM integration score and targeted therapy use was observed in metastatic non-small cell lung cancer (mNSCLC) (R2 = 0.81), an indication with a significant number of approved targeted agents. Conversely, a strong correlation between PM integration score and clinical trial enrollment was observed in metastatic triple-negative breast cancer (TNBC) (R2 = 0.63), an indication with fewer marketed targeted therapies but an active targeted therapy pipeline. Conclusion: The results in these cases suggest that PM integration is a strong indicator of high-quality care practices for both utilization of targeted therapy in more mature PM indications (e.g., mNSCLC) and clinical trial enrollment in more emerging PM indications (e.g., TNBC).Keywords
Funding Information
- Personalized Medicine Coalition
This publication has 9 references indexed in Scilit:
- Molecular Testing in Non–Small-Cell Lung Cancer: A Call to ActionJCO Oncology Practice, 2024
- Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved DrugsInternational Journal of Molecular Sciences, 2023
- Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non–Small-Cell Lung CancerJCO Precision Oncology, 2022
- Targeted therapies for cancerBMC Medicine, 2022
- New and Emerging Targeted Therapies for Advanced Breast CancerInternational Journal of Molecular Sciences, 2022
- A Quantitative Framework for Measuring Personalized Medicine Integration into US Healthcare Delivery OrganizationsJournal of Personalized Medicine, 2021
- Genomic Alteration in Metastatic Breast Cancer and Its TreatmentAmerican Society of Clinical Oncology Educational Book, 2020
- Barriers to Participation in Therapeutic Clinical Trials as Perceived by Community OncologistsJCO Oncology Practice, 2020
- Prognostic and Predictive Biomarkers: Tools in Personalized OncologyMolecular Diagnosis & Therapy, 2014